Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 2, 2004 - Issue 4
Submit an article Journal homepage
104
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluation

Losartan in diabetic nephropathy

Norberto Perico Department of Medicine and Transplantation, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. [email protected]
,
Piero Ruggenenti Department of Medicine and Transplantation, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. [email protected]
&
Giuseppe Remuzzi Department of Medicine and Transplantation, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. [email protected]
Pages 473-483 | Published online: 10 Jan 2014

References

  • Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end stage renal disease in the united states to the year 2010. J. Am. Soc. Nephrol. 12, 2753–2758 (2001).
  • Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. NephroL 13, S37—S40 (2002).
  • •Demonstrates that the total cumulative cost for renal replacement therapy in the next decade will exceed US$1 trillion worldwide.
  • Ansell D, Feest T, Byrne C. UK Renal Registry Report 1999. Ansell D, Feest T (Eds), UK Renal Registry, Bristol, UK (1999).
  • Schaubel D, Morrison H, Desmeules M et al End stage renal disease in Canada: prevalence projections to 2005. Can. Med Assoc. J. 160, 1557–1563 (1999).
  • US Renal Data System. Excerpts from the USRDS annual data report. Am. J. Kidney Dis. 36(Suppl.), S1—S239 (2000).
  • Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk Is albumin excretion rate sufficient? Diabetes 49,1399–1408 (2000).
  • National Diabetes Data Group: Diabetes in America, 2nd Edition. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, NIH Publication, ND, USA 95–1468 (1995).
  • •Analysis of the risk of overt nephropathy in Type 1 and 2 diabetic patients.
  • Mogensen CE, Chachati A, Christensen CK et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest. 9,85–95 (1985).
  • Kussman MJ, Goldstein HH, Gleason RE. The clinical course of diabetic nephropathy. J. Am. Med Assoc. 236,1861–1863 (1976).
  • Parving H-H, Osterby R, Ritz E. Diabetic nephropathy. In: The Kidney. Brenner BM (Ed.), WB Saunders, PA, USA (2000).
  • Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand. J. Clin. Lab. Invest. 36,383–388 (1976).
  • Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetes with diabetic nephropathy. Diabetologia 20,457–461 (1981).
  • Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br. Med. J. 294,1651–1654 (1987).
  • Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H. Albuminuria and poor glycemic control predicts mortality in NIDDM. Diabetes 44,1303–1309 (1995).
  • Parving H-H, Hommel E. Prognosis in diabetic nephropathy. Br. Med. J. 299, 230–233 (1989).
  • Parving H-H, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1(8335), 1175–1179 (1983).
  • Lewis E, Hunsicker L, Bain B, Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J. Med. 329,1456–1462 (1993).
  • Parving H-H, Lehnert H, Bröchner- Mortensen J, Gomis R, Andersen S, Amer P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J. Med 345,870–878 (2001).
  • ••Demonstrates that an angiotensin (AT)-1 receptor blocker reduces the incidence of overt nephropathy in hypertensive, microalbuminuric Type 2 diabetic patients.
  • Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl. J. Med. 345,851–860 (2001).
  • ••Demonstrates that an ATi-receptorantagonist is more renoprotective than a dihydropiridinic calcium channel blocker in Type 2 diabetic patients with overt nephropathy.
  • Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H. Effects of Losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. Med. 345,861–869 (2001).
  • •• ATi-receptor blockade with losartan is more renoprotective than conventional antihypertensive therapy in patients with Type 2 diabetes and overt nephropathy.
  • Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H. Remission and regression in the nephropathy of Type 1 diabetes when blood pressure is controlled aggressively. Kidney Int. 60, 277–283 (2001).
  • Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl. J. Med. 339,1448–1456 (1998).
  • Abbate M, Zoja C, Morigi M et al. In progressive nephropathy, exuberant podocyte TGFB activates a prosclerosis phenotype in mesangial cells. J. Am. Soc. Nephrol. 12, (2001) (Abstract 670A).
  • Zoja C, Morigi M, Remuzzi G. Proteinuria and phenotypic change of proximal tubular cells. J. Am. Soc. Nephrol. 14, S36—S41 (2003).
  • Eddy AA. Role of cellular infiltrates in response to proteinuria. Am. J. Kidney Dis. 37\(Suppl. 2), S25—S29 (2001).
  • Johnson DW, Saunders HJ, Baxter RC et al. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int. 54,747–757 (1998).
  • Ruggenenti P, Perna A, Mosconi L et al. Urinary protein excretion rate is the best independent predictor to ESRF in nondiabetic chronic nephropathies. Kidney Int. 53,1209–1216 (1998).
  • Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 63, 1468–1474 (2003).
  • Rossing P, Hommel E, Smidt UM, Parving H-H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42,715–719 (1993).
  • Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing end stage renal disease in patients with Type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 63,1499–1507 (2003).
  • Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria and the progression of renal disease: the Modification of Diet in Renal Disease study. Ann. Intern. Med. 123,754–762 (1995).
  • The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 349,1857–1863 (1997).
  • Ruggenenti P, Perna A, Gherardi G et al, on behalf of Gruppo Italian° di Studi Epidemiologici in Nefrologia (GISEN). Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352,1252–1256 (1998).
  • Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with nondiabetic renal disease. Kidney Int. 45\(Suppl. 4), S174—S178 (1994).
  • Hovind P, Rossing P, Tarnow L, Smidt UM, Pawing H-H. Progression of diabetic nephropathy. Kidney Int-. 59,702–709 (2001).
  • de Jong PE, Navis GJ, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 354, 352–353 (1999).
  • Ruggenenti P, Perna A, Remuzzi G. GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 63, 2254–2261 (2003).
  • Aros C, Remuzzi G. The renin—angiotensin system in progression, remission and regression of chronic nephropathies. J. Hypertens. 20\(Suppl. 3), S45—S53 (2002).
  • Yoshioka T, Rennke HG, Salant DJ, Deen WM, Ichikawa I. Role of abnormally high transmural pressure in permselectivity defect of glomerular capillary wall: a study in early Heymann nephritis. Circ. Res. 61, 531–538 (1987).
  • Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J. Am. Soc. NephroL 7, 653–660 (1996).
  • Kritz W Hackenthal E, Nobiling R, Sakai T, Elger M. A role for podocytes to counteract capillary wall distension. Kidney Int. 45,369–376 (1994).
  • Duvarsula RV, Petermann AT, Hiromura K et al Activation of a local angiotensin system in podocytes by mechanical strain. Kidney Int. 65,30–39 (2004).
  • Shake JG, Brandt RC, Daniels BS. Angiotensin II induces actin polymerization within glomerular filtration barrier: possible role in the local regulation of ultrafiltration. J. Am. Soc. Nephrol. 3,568A (1992).
  • Gloy J, Henger A, Fischer K-G et al. Angiotensin II depolarizes podocytes in the intact glomerulus of the rat. J. Clin. Invest. 99,2772–2781 (1997).
  • Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol. Died Transplant. 15(Suppl. 6), 61–63 (2000).
  • Wolf G, Ziyadeh E Renal tubular hypertrophy induced by angiotensin II. Seminar NephroL 17,448–454 (1997).
  • Wolf G, Kalluri R, Ziyadeh F, Neilson E, Stahl R. Angiotensin II induces ot3 (IV) collagen expression in cultured urine proximal tubular cells. Proc. Assoc. Am. Physic. 11,357–364(1999).
  • Strutz F, Muller GA. Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press. Res. 22,71–80 (1999).
  • Baricos WH, Cortez SL, El-Dahr SS, Schaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 47,1039–1047 (1995).
  • Keane WF, Rai JL. Relationship among altered glomerular barrier permselectivity, angiotensin II and mesangial uptake of macromolecules. Lab. Invest. 52,899–604 (1985).
  • Egido J. Vasoactive hormones and renal sclerosis. Kidney Int-. 49,578–597 (1996).
  • Okada H, Danoff T, Kalluri R, Neilson E. Early role of Fsp 1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273, F563—F574 (1997).
  • Rhaleb NE, Rouissi N, Nantel F, D'Orleans-Juste P, Regoli D. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 14,480–484 (1991).
  • •Summary of the ATi-receptor-blockade properties of losartan.
  • Simpson KL, McClellan KJ. Losartan: a review of its use, with special focus on elderly patients. Drug Aging 16,227–250 (2000).
  • Sica DA, Lo MW, Shaw WC et al The pharmacokinetics of losartan in renal insufficiency. J. Hypertens. 13\(Suppl. 1), S49—S52 (1995).
  • Sica DA, Halstenson CE, Gehr TW et al. Pharmacokinetics and blood pressure response of losartan in end stage renal disease. Clin. Pharmacoki net. 38,519–526 (2000).
  • Ooak KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51,820–845 (1996).
  • Merck & Co. Cozaar product monograph. (2001).
  • Cheetman C, °Driscoll 0, Stanton K et al. Losartan, an angiotensin Type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin. Sci. 100,13–17 (2001).
  • Devereux RB, Dahlöf B, Kjeldsen SE et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann. Intern. Med. 139,169–177 (2003).
  • ••Losartan is more effective in hypertensivepatients than atenolol in preventing cardiovascular morbidity and death independent of blood pressure reduction.
  • Deininger E, Oltmanns KM, Wellhoener P et al. Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans. Clin. PharmacoL Ther 70, 362–369 (2001).
  • Nielsen S, Dollerup J, Nielsen B et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 month study. Nephrol. Dial. Transplant. 12(Suppl. 2), 19–13 (1997).
  • Lacourciere Y, Belanger A, Godin C et al Long-term comparison of losartan and enalapril on kidney function in hypertensive Type 2 diabetics with early nephropathy. Kidney Int. 58,762–769 (2000).
  • Tan KC, Chow WS, Ai VH et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in Type 2 diabetic patients with microalbuminuria. Diabetes Metab. Res. Rev. 28,71–76 (2002).
  • de Pablos-Velasco PL, Pazos Toral F, Esmatjes JE et al. Losartan titration versus diuretic combination in Type 2 diabetic patients. J. Hypertens. 20,715–719 (2002).
  • Zandbergen AAM, Baggen MGA, Lamberts SWJ, Bootsma AH, de Zeeuw D, Ouwendijk RJT. Effect of losartan on microalbuminuria in normotensive patients with Type 2 diabetes mellitus. Ann. Intern. Med. 139, 90–96 (2003).
  • ••Provides evidence of the efficacy oflosartan in reducing albumin excretion rate in microalbuminuric normotensive patients with Type 2 diabetes.
  • Arteaga J, Petrina E, Anda E et al. The antiproteinuric effect of enalapril is potentiated by losartan in normotensive patients with diabetic nephropathy. Am. J. Hypertens. 13\(Pt 2), 117 (2000).
  • Yokota C, Kawai K, Okuda Y et al. Combination of AT1RB and ACE-I has a synergic effect on the reduction of microalbuminuria in Type 2 diabetic patients. Diabetologia 44\(Supp1.1), 276 (2001).
  • Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving H-H. Time course of antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol. Dial. Transplant. 18,293–297 (2003).
  • Buter H, Navis G, Dullaart RP, de Zeeuw D, de Jong PE. Time course of the antiproteinuric and renal hemodynamic responses to losartan in microalbuminuric IDDM. NephroL Dial. Transplant. 16, 771–775 (2001).
  • Andersen S, Tarnow L, Rossing P, Hansen BY, Pawing H-H. Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. Kidney Int. 57,601–606 (2000).
  • ••Short-term cross-over study carried out inType 1 diabetic patients with persistent albuminuria demonstrates that losartan and angiotensin-converting enzyme inhibition have similar beneficial effect on albumin excretion rate.
  • Parving H-H, Andersen S, Jacobsen P et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminar NephroL 24,147–157 (2004).
  • Andersen S, Rossing P, Juhl TR, Deinum J, Parving H-H. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol. Died Transplant. 17,1413–1418 (2002).
  • Pawing H-H, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow-up study. Br. Med. J. 313,591–594 (1996).
  • Jacobsen E Rossing K, Rossing P et al Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int-. 53, 1002–1006 (1998).
  • Penno G, Chaturvedi N, Talmud PJ et al Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 47,1507–1511 (1998).
  • Jacobsen E Tarnow L, Carstensen B, Hovind E Poirier O, Parving H-H. Genetic variation in the renin—angiotensin system and progression of diabetic nephropathy. J. Am. Soc. Nephrol 19,2843–2850 (2003).
  • Andersen S, Tarnow L, Cambien F et al Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26,1501–1506 (2003).
  • Andersen S, Tarnow L, Cambien F et al Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int. 62, 192–198 (2002).
  • •Indicates that losartan offers renoprotection independently of ACE insertion/deletion genotype in albuminuric, hypertensive Type 1 diabetic patients.
  • Lebovitz HE, Wiegmann TB, Cnaan A et al Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. (Suppl. 45), S150—S155 (1994).
  • Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kdney Int. 50,1641–1650 (1996).
  • Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and micro-HOPE substudy. Lancet 355,253–259 (2000).
  • Nielsen FS, Rossing E Gall MA, Skott P, Smidt UM, Parving H-H. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46, 1182–1188 (1997).
  • Fogari R, Zoppi A, Corradi L et al Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with Type II diabetes and impaired renal function. J. Hum. Hypertens. 13,47–53 (1999).
  • Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care 23(Suppl. 2), 5B54-5B64 (2000).
  • Merck & Co. Inc. FDA Advisory Committee recommends approval for Cozaar to delay progression of renal disease in Type 2 diabetic patients with proteinuria. Media Release 12, (2002).
  • American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Carr 25(Suppl. 1), S33—S49 (2002).
  • Herman WH, Shahinfar S, Carides GW et al, for the RENAAL Investigators. Losartan reduces the costs associated with diabetic end stage renal disease. Diabetes Care 26,683–687 (2003).
  • Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77, 1925-1930 (1986).
  • Remuzzi A, Perico N, Amuchastegui CS et al Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J. Am. Soc. 1Vephrol 4,40-49 (1993).
  • Jafar TH, Schmid CH, Landa M et al, for the Ace Inhibition in Progressive Renal Disease Study Group: angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann. Intern. Med 135,73–87 (2001).
  • Pawing H-H. Diabetic nephropathy: prevention and treatment. Kidney Int. 60, 2041–2055 (2001).
  • Ruggenenti P, Mosconi L, Sangalli F et al Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int. 55,984–994 (1999).
  • Chan JCN, Wat NMS, Therefore W-Y et al Renin angiotensin aldosterone system blockade and renal disease in patients with Type 2 diabetes. An Asian perspective from the RENAAL study. Diabetes Care 27, 874–879 (2004).
  • Ruggenenti E Perna A, Remuzzi G, on behalf of Gruppo Italian ° di Studi Epidemiologici in Nefrologia (GISEN). ACE inhibitors to prevent end stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. J. Am. Soc. Nephrol 12,2832–2837 (2001).
  • Hostetter TH. The next treatments of chronic kidney disease: if we find them, can we test them? J. Am. Soc. Nephrol 13,3024–3026 (2002).
  • Buckalew V, Martinez F, Altamirano J, Roniker J, Kleiman J, Krause S. The selective aldosterone blocker eplerenone is effective as monotherapy or adjunctive therapy in diabetic hypertensive with microalbuminuria. Diabetes 51\(Suppl. 2), A38 (2002).
  • Ruggenenti E Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 357,1601–1608 (2001).
  • Orth SR, Stockmann A, Conradt C. Smoking as a risk factor for end stage renal failure in men with primary renal disease. Kidney Int. 54,926–931 (1998).
  • Pechter U, Ots M, Mesikepp S, Zilmer K et al Beneficial effects of water-based exercise in patients with chronic kidney disease. Int. J. Rehabil Res. 26,153–156 (2003).

Websites

  • Statistical review and evaluation — Cozaar® (Lozartan). NDA 20–386 www.fda.gov/ohrms/dockets/ac/02/briefing/3 84961_04_statistical%20review%20addendu m.htm ical%20review.pdf (Accessed June 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.